Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

468
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
468
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

527
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
527
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

806
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
806
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.3K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.3K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

899
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
899
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

917
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
917

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Conserved T cell receptor usage underpins recognition of CD1c presenting a mycobacterial lipid.

bioRxiv : the preprint server for biology·2026
Same author

Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials.

The Lancet. Microbe·2026
Same author

BCG vaccination induces antibacterial effector functions among Vδ1/3 T cells that are associated with protection against tuberculosis.

Cell reports. Medicine·2026
Same author

IFN-γ- GranzymeB + Natural killer cells are induced by IV BCG vaccination and associated with protection against tuberculosis in rhesus macaques.

Mucosal immunology·2025
Same author

Infant CD4 T-Cell Response to SARS-CoV-2 mRNA Vaccination Is Restricted in Cytokine Production and Modified by Vaccine Manufacturer.

Open forum infectious diseases·2025
Same author

Infant CD4 T-cell response to SARS-CoV-2 mRNA vaccination is restricted in cytokine production and modified by vaccine manufacturer.

bioRxiv : the preprint server for biology·2025

Video Experimental Relacionado

Updated: Jan 10, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.9K

Un enfoque sistemático para el desarrollo de vacunas contra la tuberculosis

Chetan Seshadri1

  • 1Department of Medicine, University of Washington School of Medicine, Seattle, WA 98109, USA.

Cell
|November 27, 2025
PubMed
Resumen

Una nueva vacuna de ARNm trivalente es prometedora contra la tuberculosis (TB), un asesino infeccioso líder. Esta nueva vacuna proporciona una protección duradera en ratones y aumenta la eficacia de la vacuna BCG existente.

Más Videos Relacionados

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.5K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K

Videos de Experimentos Relacionados

Last Updated: Jan 10, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.9K
Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.5K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K

Área de la Ciencia:

  • Inmunología
  • Vacunas y vacunas
  • Enfermedades infecciosas

Sus antecedentes:

  • La tuberculosis (TB) sigue siendo una gran amenaza para la salud mundial, causando una mortalidad significativa en todo el mundo.
  • La vacuna actual de Bacillus Calmette-Guérin (BCG) ofrece una protección variable contra la tuberculosis.
  • Hay una necesidad urgente de vacunas más eficaces contra la tuberculosis.

Objetivo del estudio:

  • Identificar nuevos antígenos para una vacuna mejorada contra la tuberculosis.
  • Desarrollar y evaluar una nueva vacuna trivalente de ARNm contra la TB.
  • Para evaluar la eficacia de la vacuna sola y en combinación con BCG.

Principales métodos:

  • Evaluación sistemática de 42 antígenos candidatos para el Mycobacterium tuberculosis.
  • Desarrollo de una formulación de vacuna de ARNm trivalente.
  • Prueba de la eficacia de la vacuna en múltiples modelos de tuberculosis en ratones.
  • Evaluación de la protección conferida por la vacuna de ARNm y su sinergia con la BCG.

Principales resultados:

  • La vacuna de ARNm trivalente desarrollada demostró una protección efectiva y duradera contra la tuberculosis en modelos de ratón.
  • La vacuna de ARNm mejoró significativamente la inmunidad protectora proporcionada por la vacuna BCG.
  • Se identificaron y validaron antígenos específicos para su papel en la inmunidad protectora.

Conclusiones:

  • Una nueva vacuna trivalente de ARNm representa una estrategia prometedora para la prevención de la tuberculosis.
  • La terapia combinada con la nueva vacuna de ARNm y BCG puede ofrecer una protección superior.
  • El desarrollo de esta vacuna de ARNm tiene potencial para controlar la epidemia mundial de tuberculosis.